NCT07271667
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07271667
Title A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Curis, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | ESP

Facility Status City State Zip Country Details
Mt Sinai Comprehensive Cancer Center RECRUITING Miami Beach Florida 33140 United States Details
Mayo Clinic RECRUITING Rochester Minnesota 55905 United States Details
Summit Medical Group RECRUITING Florham Park New Jersey 07932 United States Details
Ohio State University Comprehensive Cancer Center RECRUITING Columbus Ohio 43210 United States Details
UPMC Hillman Cancer Center RECRUITING Pittsburgh Pennsylvania 15232 United States Details
Texas Oncology - Sammons Cancer Center RECRUITING Dallas Texas 75246 United States Details
IRCCS Ospedale San Raffaele RECRUITING Milan 20132 Italy Details
Azienda Ospedaliero Universitaria Maggiore Della Carità RECRUITING Novara 28100 Italy Details
Azienda Ospedale Università Padova RECRUITING Padova 35128 Italy Details
MD Anderson Cancer Center Madrid RECRUITING Madrid 28033 Spain Details
Hospital Universitario Fundación Jiménez Díaz - START MADRID RECRUITING Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field